Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov7310.25208/0042-4609-2014-90-5-106-111DRUG TREATMENT IN DERMATOVENEROLOGYФАРМАКОТЕРАПИЯ В ДЕРМАТОВЕНЕРОЛОГИИTopical forms of sertaconazole in the treatment of fungal infections of the skinТопические формы сертаконазола в терапии грибковых заболеваний гладкой кожиMatushevskayaE. V.МатушевскаяЕ. В.
Russian Federation
matushevskaya@mail.ruSvyrzhevskayaE. V.СвирщевскаяЕ. В.
Russian Federation
Institute of Improvement of professional skill of Federal Medico-Biological Agency of RussiaФГБОУ ДПО «Институт повышения квалификации Федерального медико-биологического агентства»M.M. Shemyakin and Yu.A. Ovchinnikov Institute of bioorganic chemistry of the Russian Academy of SciencesФГБУН «Институт биоорганической химии им. М.М. Шемякина и Ю.В. Овчинникова» Российской академии наук2410201490510611124082017Copyright ©; 2014, Matushevskaya E.V., Svyrzhevskaya E.V.Copyright ©; 2014, Матушевская Е.В., Свирщевская Е.В.2014Matushevskaya E.V., Svyrzhevskaya E.V.Матушевская Е.В., Свирщевская Е.В.https://creativecommons.org/licenses/by/4.0https://vestnikdv.ru/jour/article/view/73

The data of foreign and domestic clinical studies on the efficacy and safety of sertaconazole (SK)is discussed. Broad spectrum of activity of SK and lack of resistance to the drug is established. Several studies opens new opportunities for the SK for the treatment of dermatosis, in the pathogenesis of which play an important role of opportunistic infection. High efficiency and compliance, a significantly greater safety index than that of the other members of the azole group, suggest the SK as a formulation that extends the capabilities of the outer antimycotic therapy of fungal infections of the skin.

Представлены данные зарубежных и отечественных клинических исследований по изучению эффективности и безопасности сертаконазола (СК). Приведены исследования, которые показывают широкий спектр действия СК к практически всем грибковым агентам и отсутствие резистентности к препарату. Ряд исследований открывает новые возможности применения СК для лечения дерматозов, в патогенезе которых отводится важная роль оппортунистической инфекции. Высокая эффективность и комплаентность, значительно больший индекс безопасности, чем у других представителей группы азолов, позволяют говорить о СК как о препарате, который расширяет возможности наружной антимикотической терапии грибковых заболеваний кожи.

микозытопическая терапияклинико-микробиологические исследованиясертаконазолmycosistopical therapyclinical and microbiological studiessertaconazolePiraccini B.M., Gianni C. Update on the management of onychomycosis. G Ital Dermatol Venereol. 2013 Dec; 148 (6): 633-8.Agut J. et al. Direct membrane damaging effect of Sertaconazole on Candida albicans as a mechanism of its fun_gicidal activity. Arzneim. Forsch. Drug Res. 1992; 42: 721-724.Farre M., Ugena B., Badenas J.M. et al. Pharmacokineticsand tolerance of sertaconazole in man after repeated percutaneous admin-istration.Arzneimittelforschung. 1992; 42: 752-754.Carrillo-Munoz A.J., Tur-Tur C., Cardenes D.C., Estivill D., Giusiano G. Sertaconazole nitrate-shows fungicidal and fungistatic activities against Trichophytonrubrum, Trichophyton mentagrophytes, and Epidermophyton loccosum, causative agent soft in eapedis. Antimicrob Agents Chemother. 2011; 55 (9): 4420-4431.Сarrilo-Muñoz A.J., Tur C., Torres J. In-vitro antifungal activity of sertaconazole, bifonazole, ketoconazole, and miconazole against yeasts of the Candida genus. J Antimicrob Chemother. 1996; 37 (4): 815-819.Carillo-Muñoz A.J., Tur-Tur C. Comparative study of antifungal activity of sertaconazole, terbinafine, and bifonazole against clinical isolates of Candida spp., Cryptococcus neoformans and dermatophytes. Chemotherapy. 1997; 43 (6): 387-392.Carrillo-Muñoz A.J., Tur-Tur C., Bornay-Llinares F.J., Arévalo P. Comparative study of the in vitro antifungal activity of bifonazole, nafti-fine and sertaconazole against yeasts. J Chemother. 1999 Jun; 11 (3): 187-190.Croxtall J.D., Plosker G.L. Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs. 2009; 69 (3): 339-359.Sur R., Babad J.M., Garay M., Liebel F.T., Southall M.D. Anti-inflammatory activity of sertaconazole nitrate is mediated via activation of a p38-COX-2-PGE2 pathway. J Invest Dermatol. 2008; 128 (2): 336-344.Borelli C., Korting H.C., Bödeker R.H., Neumeister C. Safety and efficacy of sertaconazole nitrate cream 2% in the treatment of tinea pedis interdigitalis: a subgroup analysis. Cutis 2010; 85: 2: 107-111.Goryachkina M.V., Belousova T.A., Potekaev N.N. Sertaconazole in the topical treatment of superficial fungal infections of the skin. Clinical Derm and Venereol, 2012, 5, 42-47. [Горячкина М.В., Белоусова Т.А., Потека-ев Н.Н. Сертаконазол вместном лечении поверхностных микозов кожи. Клин дерматол венерол, 2012, 5, 42-47].Susilo R., Korting H.C., Strauss U.P. et al. Dermatomycoses of the glabrous skin: adouble-blind, randomised, comparative trial of sertacon-azole 2% cream once daily versus vehicle. Clin Drug Investig 2003; 23 (6): 387-394.Ghaninejad H., Gholami K., Hashemi P., Hajibabai M., Rahbar Z., Farivar M.S., Mastani F., Rashidi A. Sertaconazole 2% cream vs. miconazole 2% cream for cutaneous mycoses: a double-blind clinical trial. Clin Exp Dermatol. 2009; 34 (8): e837-9.Sharma A., Saple D.G., Surjushe A., Rao G.R., Kura M., Ghosh S., Bolmall C., Baliga V. Efficacy and tolerability of sertaconazole nitrate 2% cream vs. miconazole in patients with cutaneous dermatophytosis. Mycoses. 2011; 54 (3): 217-222.Alomar C., Bassas S., Casas M. et al. Multicentre doubleblind trial on the efficacy and safety of sertaconazole 2% cream in comparison with miconazole 2% cream on patients suffering from cutaneous mycoses. Arzneimittelforschung 1992; 42 (5A): 767-737.Jerajani H., Janaki C., Kumar S., Phiske M. Comparative assessment of the efficacy and safety of sertaconazole (2%) cream versus ter-binafine cream (1%) versus luliconazole (1%) cream in patients with dermatophytoses: a pilot study. Indian J Dermatol. 2013; 58 (1): 34-38.Goldust M., Rezaee E., Rouhani S. Double blind study of sertaconazole 2% cream vs. clotrimazole 1% cream in treatment of seborrheic dermatitis. Ann Parasitol. 2013; 59 (1): 25-29.Goldust M., Rezaee E., Raghifar R., Hemayat S. Treatment of seborrheic dermatitis: the efficiency of sertaconazole 2% cream vs. tacrolimus 0.03% cream. Ann Parasitol. 2013; 59 (2): 73-77.Goldust M., Rezaee E., Raghifar R. Treatment of seborrheic dermatitis: comparison of sertaconazole 2% cream versus pimecrolimus 1 % cream. Ir J Med Sci. 2013; 182 (4): 703-706.Goldust M., Rezaee E., Masoudnia S., Raghifar R. Clinical study of sertaconazole 2% cream vs. hydrocortisone 1% cream in the treatment of seborrheic dermatitis. Ann Parasitol. 2013; 59 (3): 119-123.Goldust M., Rezaee E., Raghifar R. A double blind study of the effectiveness of sertacon-azole 2% cream vs. metronidazole 1% gel in the treatment of seborrheic dermatitis. Ann Parasitol. 2013; 59 (4): 173-177.Goldust M., Rezaee E., Rouhani S. Double blind study of sertaconazole 2% cream vs. clotrimazole 1% cream in treatment of seborrheic dermatitis. Ann Parasitol. 2013; 59 (1): 25-29.Borelli C., Klovekorn G., Ernst T.M. et al. Comparative study of 2% sertaconazole solution and cream formulations in patients with tinea corporis, tinea pedis interdigitalis, or a corresponding candidosis. Am J Clin Dermatol 2007; 8 (6): 371-378.http://www.grls.rosminzdrav.ru/Grls_View.aspx?idReg=85014&is0ld=1&t=